Log in

NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Forecast & News

$0.34
+0.01 (+3.01 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$0.29
Now: $0.34
$0.36
50-Day Range
$0.33
MA: $0.49
$0.62
52-Week Range
$0.29
Now: $0.34
$3.24
Volume3.89 million shs
Average Volume1.58 million shs
Market Capitalization$19.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Read More
HTG Molecular Diagnostics logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.20 million
Book Value$0.74 per share

Profitability

Net Income$-16,450,000.00
Net Margins-100.45%

Miscellaneous

Employees107
Market Cap$19.84 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.


HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

How has HTG Molecular Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HTGM stock has decreased by 13.3% and is now trading at $0.3419. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of HTG Molecular Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HTG Molecular Diagnostics.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) announced its quarterly earnings results on Wednesday, March, 25th. The medical research company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. HTG Molecular Diagnostics had a negative net margin of 100.45% and a negative return on equity of 96.67%. View HTG Molecular Diagnostics' earnings history.

What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?

HTG Molecular Diagnostics issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.2-19.2 million, compared to the consensus revenue estimate of $19.38 million.

What price target have analysts set for HTGM?

4 equities research analysts have issued twelve-month target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $0.70 to $6.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $2.43 in the next twelve months. This suggests a possible upside of 609.3% from the stock's current price. View analysts' price targets for HTG Molecular Diagnostics.

What are Wall Street analysts saying about HTG Molecular Diagnostics stock?

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
  • 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (3/17/2020)
  • 2. Canaccord Genuity analysts commented, "We were pleased to host newer HTG CEO John Lubniewski and CFO Conference last week in Boston. Our key takeaways: (1) HTG is making a bigger push to develop and launch novel diagnostic test launches in breast and lung cancer; (2) HTG is not getting any credit in its stock price for strong 80%+ Y/Y growth in its base RUO profiling business; and (3) HTG has taken adverse lumps" because they haven’t converted a CDx yet (yet they have over 70 active global pharma programs). We reiterate our BUY rating and trim our PT to $3, which we would be inclined to raise should HTG hit" on one of its pharma collaborations. EdgeSeq Breast Total Lung." (8/13/2019)
  • 3. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $237M. This includes an asset value at $247M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate, excluding $10M debt." (6/18/2019)

Has HTG Molecular Diagnostics been receiving favorable news coverage?

Media headlines about HTGM stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. HTG Molecular Diagnostics earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutHTG Molecular Diagnostics.

Who are some of HTG Molecular Diagnostics' key competitors?

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Aurinia Pharmaceuticals (AUPH), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Gilead Sciences (GILD), MEI Pharma (MEIP), Marinus Pharmaceuticals (MRNS), Resonant (RESN) and FleetMatics Group (FLTX).

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
  • Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)
  • Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (4.35%), Cowen Prime Services LLC (3.68%), Geode Capital Management LLC (0.66%) and HighMark Wealth Management LLC (0.33%). View institutional ownership trends for HTG Molecular Diagnostics.

Which major investors are buying HTG Molecular Diagnostics stock?

HTGM stock was purchased by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, HighMark Wealth Management LLC, Perkins Capital Management Inc., and Geode Capital Management LLC. View insider buying and selling activity for HTG Molecular Diagnostics.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $0.34.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $19.84 million and generates $19.20 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe. View additional information about HTG Molecular Diagnostics.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is http://www.htgmolecular.com/.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.


MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel